MENU
Adrenal Cancer Clinical Trials
At the University of Michigan Rogel Cancer Center, our Endocrine Oncology Program has studies underway for those with adrenal cancer. We have extensive experience in selecting the right trial for each person. Below is a list of some of the open trials. If you see one you may be eligible for or have questions, please call 800-865-1125 (Monday-Friday, 8am-5pm EST).
Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers; UMCC 2017.003
The principle investigator for this trial is Francis Worden, M.D. Get more information about this trial's purpose, eligibility and more by visiting the UMCC 2017.003 clinical trial page.
A Multicenter, Randomized, Double-blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile; UMCC 2015.162
The principle investigator for this trial is Francis Worden, M.D. Get more information about this trial's purpose, eligibility and more by visiting the UMCC 2015.162 clinical trial page.
Molecular Analysis for Therapy Choice (MATCH); ECOG-ACRIN EAY131
The principle investigator for this trial is Ajjai Alva, M.D. Get more information about this trial's purpose, eligibility and more by visiting the ECOG-ACRIN EAY131 clinical trial page.